---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-23-000060"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2023-09-28T23:59:59+00:00"
generated_at: "2026-06-10T07:37:55.578575+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elicio reports ELI-002 Phase 1 data: median RFS not reached vs 3.9 months, HR=0.14

## Summary
- Median RFS not reached for high T cell responders vs 3.9 months for low (HR=0.14; p=0.013).
- 86% reduction in risk of progression or death in patients with large T cell responses.
- Tumor biomarker reduction/clearance -86.9% vs -1.0% in above vs below median T cell responders (p<0.0017).
- Plan to initiate randomized Phase 2 study of ELI-002 7P in adjuvant PDAC patients early 2024.
- No ≥Grade 3 treatment-related AEs; safety profile supports further development.

## SEC filing metadata
- accession: 0001601485-23-000060
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2023-09-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000060/0001601485-23-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000060/angn-20230927.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-23-000060
- JSON: https://secwatch.observer/filing/0001601485-23-000060.json
- Plain text: https://secwatch.observer/filing/0001601485-23-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.